{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:58:52Z","timestamp":1791561532597,"version":"4.3.4"},"reference-count":81,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute psychotic symptoms like delusions and hallucinations are of major concern while treating patients with schizophrenia and alzheimer's psychosis, primarily impacting their daily life functioning and quality of life. The traditional antipsychotic medications, commonly prescribed to manage these symptoms, cause significant side effects with limited efficacy, requiring novel therapeutic agents that can overcome this challenge. While there is no definitive cure, symptomatic treatment can help relieve some of the symptoms and improve the quality of life of people with alzheimer's disease (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A comprehensive literature search of PubMed, scopus, google scholar, and ClinicalTrials.gov was conducted to identify studies on xanomeline\u2013trospium chloride (KarXT) in schizophrenia and AD psychosis. After screening 802 unique records, 39 studies\u2014including preclinical, clinical, and observational investigations\u2014were included in this narrative review. Only English\u2010language publications up to February 2025 were considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>KarXT, with its dual action on the M1 and M4 receptors and mAChR antagonism, greatly helps reduce the severity of the positive and negative symptoms, as it resulted in an 8.4\u2010point greater reduction on the PANSS scale. Side effects were minimal and did not account for the discontinuation of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Psychosis is a common feature of schizophrenia and AD, most often caused by high concentrations of dopamine in the brain, characterized by hallucinations, delusions, and disorganized thinking, resulting in markedly reduced quality of life for the patient and associated caregiver. Conventional treatments targeting dopamine receptors produce extrapyramidal symptoms and metabolic side effects, leading to noncompliance with medication. KarXT, with its dual action on M1 and M4 receptors and mAChR antagonism, greatly helps reduce the severity of the positive and negative symptoms. The side effects experienced were minimal and did not account for the discontinuation of treatment.An overview of the mechanism of action, clinical trials, and classical findings of KarXT for the management of psychotic symptoms in patients with schizophrenia and alzheimer's disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.71182","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:55:39Z","timestamp":1768546539000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring Adjunctive Novel Therapeutic Approach of KarXT (Xanomeline\u2010Trospium Chloride) for Managing Psychotic Symptoms in Patients With Schizophrenia and Alzheimer's Disease"],"prefix":"10.1002","volume":"16","author":[{"given":"Ashir","family":"Kanwal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Liaquat University of Medical and Health Sciences  Jamshoro Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bismah","family":"Azeem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Avicenna Medical College  Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Nasir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Mumtaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Liaquat University of Medical and Health Sciences  Jamshoro Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nauman","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Ozark Center  Joplin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Hammad Jaber","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Alzaiem Alazhari University  Khartoum North Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warisha","family":"Kanwal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Karachi Medical and Dental College  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal Wazir","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Khyber Medical College, Peshawar  Khyber Pakhtunkhwa Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"e_1_2_21_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_2_21_3_1","unstructured":"\u201cA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT\u20102).\u201d Accessed: Feb. 23 2025. [Online]. Available:https:\/\/ctv.veeva.com\/study\/a\u2010study\u2010to\u2010assess\u2010efficacy\u2010and\u2010safety\u2010of\u2010karxt\u2010for\u2010the\u2010treatment\u2010of\u2010psychosis\u2010associated\u2010with\u2010alzhei\u20101."},{"key":"e_1_2_21_4_1","unstructured":"\u201cA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT\u20104).\u201d Accessed: Feb. 23 2025. [Online]. Available:https:\/\/ctv.veeva.com\/study\/a\u2010study\u2010to\u2010evaluate\u2010karxt\u2010as\u2010a\u2010treatment\u2010for\u2010psychosis\u2010associated\u2010with\u2010alzheimers\u2010disease."},{"key":"e_1_2_21_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706780"},{"key":"e_1_2_21_6_1","volume-title":"\u201cAlzheimer's Disease Fact Sheet","year":"2023"},{"key":"e_1_2_21_7_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association Task Force on DSM\u2010IV","year":"2000"},{"key":"e_1_2_21_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300151"},{"key":"e_1_2_21_9_1","unstructured":"Antipsychotic medicines for psychotic disorders.https:\/\/www.who.int\/teams\/mental\u2010health\u2010and\u2010substance\u2010use\/treatment\u2010care\/mental\u2010health\u2010gap\u2010action\u2010programme\/evidence\u2010centre\/psychosis\u2010and\u2010bipolar\u2010disorders\/antipsychotic\u2010medicines\u2010for\u2010psychotic\u2010disorders#:~:text=Oral%20antipsychotic%20medicines%20%E2%80%93%20namely%20aripiprazole side%2Deffects%20and%20individual%20preference."},{"key":"e_1_2_21_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.CON.0000466662.89908.e7"},{"key":"e_1_2_21_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/S40261\u2010024\u201001377\u20109"},{"key":"e_1_2_21_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010021\u201000816\u20105"},{"key":"e_1_2_21_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(18)30039\u20105"},{"key":"e_1_2_21_14_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2018.30"},{"key":"e_1_2_21_15_1","unstructured":"Barry E. andCJewett.2024. \u201cF.D.A. approves the First New Schizophrenia Drug in Decades.\u201dThe New York times [Internet]. [cited 2025 Feb 5]; Available from:.https:\/\/www.nytimes.com\/2024\/09\/26\/health\/fda\u2010schizophrenia\u2010drug.html."},{"key":"e_1_2_21_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.7b00001"},{"key":"e_1_2_21_17_1","unstructured":"Bms.com.[cited 2025 Feb 5]. Available from:.https:\/\/news.bms.com\/news\/details\/2023\/Bristol\u2010Myers\u2010Squibb\u2010Strengthens\u2010Neuroscience\u2010Portfolio\u2010with\u2010Acquisition\u2010of\u2010Karuna\u2010Therapeutics\/default.aspx."},{"key":"e_1_2_21_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"e_1_2_21_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017015"},{"key":"e_1_2_21_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010023\u201006362\u20102"},{"key":"e_1_2_21_21_1","unstructured":"\u201cBristol Myers Squibb\u2014Bristol Myers Squibb Presents New Interim Long\u2010Term Efficacy Data from the EMERGENT\u20104 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society.\u201d Accessed: Feb. 22 2025. [Online]. Available:https:\/\/news.bms.com\/news\/details\/2024\/Bristol\u2010Myers\u2010Squibb\u2010Presents\u2010New\u2010Interim\u2010Long\u2010Term\u2010Efficacy\u2010Data\u2010from\u2010the\u2010EMERGENT\u20104\u2010Trial\u2010Evaluating\u2010KarXT\u2010in\u2010Schizophrenia\u2010at\u2010the\u20102024\u2010Annual\u2010Congress\u2010of\u2010the\u2010Schizophrenia\u2010International\u2010Research\u2010Society\/default.aspx?utm_source=chatgpt.com."},{"key":"e_1_2_21_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460\u20109568.2003.02588.x"},{"key":"e_1_2_21_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008016.pub36"},{"key":"e_1_2_21_24_1","doi-asserted-by":"publisher","DOI":"10.2471\/blt.07.045377"},{"key":"e_1_2_21_25_1","unstructured":"ClinicalTrials.gov ID: NCT05511363.https:\/\/clinicaltrials.gov\/study\/NCT05511363."},{"key":"e_1_2_21_26_1","unstructured":"\u201cCobenfy: A New Antipsychotic | CARLAT PUBLISHING.\u201d Accessed: Mar. 20 2025. [Online]. Available:https:\/\/www.thecarlatreport.com\/blogs\/2\u2010the\u2010carlat\u2010psychiatry\u2010podcast\/post\/4842\u2010cobenfy\u2010a\u2010new\u2010antipsychotic?utm_source=chatgpt.com."},{"key":"e_1_2_21_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537\u2010022\u201000320\u20101"},{"key":"e_1_2_21_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370"},{"key":"e_1_2_21_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/D41586\u2010024\u201003123\u20109"},{"key":"e_1_2_21_30_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200544070\u201000003"},{"key":"e_1_2_21_31_1","unstructured":"\u201cEvaluating Pooled Data from the EMERGENT Study Programs.\u201dAccessed: Jan. 31 2025. [Online]. Available:.https:\/\/www.psychiatrist.com\/news\/evaluating\u2010pooled\u2010data\u2010from\u2010the\u2010emergent\u2010study\u2010programs\/."},{"key":"e_1_2_21_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.11.013"},{"key":"e_1_2_21_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000008243"},{"key":"e_1_2_21_34_1","unstructured":"\u201cFDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia | FDA.\u201d Accessed: Feb. 23 2025. [Online]. Available:https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010drug\u2010new\u2010mechanism\u2010action\u2010treatment\u2010schizophrenia."},{"key":"e_1_2_21_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318166c4d5"},{"key":"e_1_2_21_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172371313"},{"key":"e_1_2_21_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32279\u201074"},{"key":"e_1_2_21_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(15)00258\u20106"},{"key":"e_1_2_21_39_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"e_1_2_21_40_1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216158s000lbl.pdf."},{"key":"e_1_2_21_41_1","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216158s000lbl.pdf."},{"key":"e_1_2_21_42_1","doi-asserted-by":"publisher","DOI":"10.1176\/APPI.FOCUS.18306"},{"key":"e_1_2_21_43_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14458"},{"key":"e_1_2_21_44_1","unstructured":"\u201cKarXT | ALZFORUM.\u201d Accessed: Mar. 20 2025. [Online]. Available:https:\/\/www.alzforum.org\/therapeutics\/karxt."},{"key":"e_1_2_21_45_1","unstructured":"\u201cKarXT in Psychosis Associated With Alzheimer's Disease\u2014Clinical Trials Registry\u2014ICH GCP.\u201d Accessed: Feb. 22 2025. [Online]. Available:https:\/\/ichgcp.net\/clinical\u2010trials\u2010registry\/NCT06126224?utm_source=chatgpt.com."},{"key":"e_1_2_21_46_1","unstructured":"\u201cKarXT in Psychosis Associated With Alzheimer's Disease\u2014Clinical Trials Registry\u2014ICH GCP.\u201d Accessed: Feb. 22 2025. [Online]. Available:https:\/\/clinicaltrials.gov\/study\/NCT05980949#study\u2010overview."},{"key":"e_1_2_21_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)02190\u20106"},{"key":"e_1_2_21_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785"},{"key":"e_1_2_21_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/D41573\u2010024\u201000155\u20108"},{"key":"e_1_2_21_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyae059.279"},{"key":"e_1_2_21_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2334424"},{"key":"e_1_2_21_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)31363\u20106"},{"key":"e_1_2_21_53_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123289"},{"key":"e_1_2_21_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527\u20103458.2003.tb00247.x"},{"key":"e_1_2_21_55_1","unstructured":"\u201cMuch Ado About Something: Why There's Excitement Behind Novel Mechanism of Action in Schizophrenia.\u201d Accessed: Mar. 20 2025. [Online]. Available:https:\/\/www.psychiatrictimes.com\/view\/much\u2010ado\u2010about\u2010something\u2010excitement\u2010behind\u2010novel\u2010mechanism\u2010action\u2010schizophrenia?utm_source=chatgpt.com."},{"key":"e_1_2_21_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.08.020"},{"key":"e_1_2_21_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12273"},{"key":"e_1_2_21_58_1","unstructured":"\u201cPsychosis: The Other Big Alzheimer's Therapeutic Target\u2014BioSpace.\u201d Accessed: Jan. 31 2025. [Online]. Available:https:\/\/www.biospace.com\/alzheimer\u2010s\u2010related\u2010psychosis\u2010the\u2010other\u2010big\u2010therapeutic\u2010target."},{"key":"e_1_2_21_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010021\u201001000\u20101"},{"key":"e_1_2_21_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e3181602fe6"},{"key":"e_1_2_21_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010631.pub2"},{"key":"e_1_2_21_62_1","unstructured":"Schizophrenia.https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/schizophrenia."},{"key":"e_1_2_21_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.35.1.27"},{"key":"e_1_2_21_64_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205013666160720112608"},{"key":"e_1_2_21_65_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1508846112"},{"key":"e_1_2_21_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010019\u20100519\u20107"},{"issue":"10","key":"e_1_2_21_67_1","first-page":"43","article-title":"Xanomeline and Trospium: a Potential Fxed Drug Combination (FDC) for Schizophrenia\u2014A Brief Review of Current Data","volume":"19","author":"Singh A.","year":"2022","journal-title":"Innov Clin Neurosci"},{"key":"e_1_2_21_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100068"},{"key":"e_1_2_21_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742\u20101241.2010.02433.x"},{"key":"e_1_2_21_70_1","unstructured":"\u201cStudy Details | A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia | ClinicalTrials.gov.\u201d Accessed: Feb. 22 2025. [Online]. Available:https:\/\/www.clinicaltrials.gov\/study\/NCT03697252."},{"key":"e_1_2_21_71_1","unstructured":"\u201cTherapeutic Areas | BMS Science | HCP Site.\u201d Accessed: Feb. 23 2025. [Online]. Available:https:\/\/www.bmsscience.com\/therapeutic\u2010area\/neuroscience\/alzheimers\u2010disease\/?mol=karxt&nct=NCT05511363."},{"key":"e_1_2_21_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15069"},{"key":"e_1_2_21_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010008\u20101124\u20109"},{"key":"e_1_2_21_74_1","unstructured":"\u201cUW Clinical Trials Institute | New schizophrenia drug could treat Alzheimer's disease.\u201d Accessed: Feb. 17 2025. [Online]. Available:https:\/\/uwclinicaltrials.org\/2024\/11\/21\/new\u2010schizophrenia\u2010drug\u2010could\u2010treat\u2010alzheimers\u2010disease\/."},{"key":"e_1_2_21_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.606656"},{"key":"e_1_2_21_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/PH17050610\/S1"},{"key":"e_1_2_21_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/IJNP\/PYAE059.636"},{"key":"e_1_2_21_78_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14316"},{"key":"e_1_2_21_79_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.88482"},{"key":"e_1_2_21_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/1179573520907397"},{"key":"e_1_2_21_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.006"},{"key":"e_1_2_21_82_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22\u201015\u201006347.2002"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.71182","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/brb3.71182","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.71182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:48:19Z","timestamp":1791560899000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.71182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/brb3.71182"],"URL":"https:\/\/doi.org\/10.1002\/brb3.71182","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.71182\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.71182\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.71182\/v1\/review2","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71182"}}